Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
Annovis Bio Inc. a late-stage clinical drug platform company specializing in transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), is pleased to announce the addition of four accomplished professionals to its executive team. Despite recording a cumulative net loss of $48 million during the 12 months ending in the first quarter of 2024, resulting in a negative return on investment (ROI) of -524.18%, the company remains optimistic about its future prospects. However, it is worth noting that within the Healthcare sector, there are 577 other companies that have a higher return on investment, indicating room for improvement. Furthermore, the company’s total ranking in terms of ROI has deteriorated from 3307 in the fourth quarter of 2023 to 3330 currently.
Comments